Boston, MA Related Beal and Jamestown completed more than 260,000 s/f of life science leasing at the Innovation and Design Building (The IDB) located within the Raymond L. Flynn Marine Park (RLFMP) in the city’s Eastern Seaport neighborhood.

“We continue to see incredible demand for life science space in Boston from leading biotech companies and we’re thrilled for them to conduct important research within the historic Innovation and Design Building,” said Steve Faber, executive vice president at Related Beal. “Together with Jamestown, we are serving a critical need in the life science ecosystem by providing first-class R&D space for a variety of users including small and medium sized firms allowing them to grow rapidly and execute their business plans, resulting in tomorrow’s medical breakthroughs.”

“The unique mix and dense concentration of creative and scientific firms at The IDB makes for a truly dynamic environment,” said Dana Griffin, director of asset management and development for New England at Jamestown. “These deals validate the property as a premier location for the scientific community and continue the property’s legacy as a center of innovation.”

The nine leases will bring more than 700 jobs to the neighborhood and include:

• Entrada Therapeutics, a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, which leased 81,400 s/f;

• Shape Therapeutics, a biotech company developing RNA technologies, which leased 36,500 s/f;

• Jnana Therapeutics, a biotech company focused on developing best-in-class therapies to treat a wide range of diseases, which leased 36,400 s/f;

• Ratio Therapeutics, a discovery-stage biotechnology company developing best-in-class targeted radiotherapeutics for the treatment of cancer, which leased 19,000 s/f;

• Vedere Bio II, a biopharmaceutical company developing gene therapy products to restore functional vision to patients who have suffered vision loss, which leased 18,900 s/f;

• Seeker Biologics, a biotech company focused on developing next generation biologics for the treatment of autoimmune, allergic, and other inflammatory diseases, which leased 18,300 s/f;

• Elektrofi, a biotech company focused on drug formulation and delivery innovations, which leased 18,200 s/f;

• Aktis Oncology, a biotech company focused on the development of a new class of targeted radiopharmaceuticals to treat a broad range of cancers, which leased 17,900 s/f; and

• Hotspot Therapeutics, a biotech company exploring the discovery and development of ?rst-in-class therapies targeting nature’s regulatory sites, which leased 17,300 s/f.

Jamestown purchased The IDB in 2013 and invested more than $200 million in the revitalization of the building. Since the announcement of Jamestown’s joint venture with Related Fund Management in 2020, the firms have invested substantially more to further enhance the property, in order to attract and retain research-based life science and creative companies. The IDB is now home to the Boston Design Center and a mix of companies including architecture and creative studios, manufacturing, research and development firms, and technology startups.